Novo plumpness drug seen with 43 percent possibility of approval

<p>COPENHAGEN (Reuters) – Danish organisation <span>Novo Nordisk</span>‘s diabetes drug Victoza has a 43 percent possibility of being authorized as an <span>obesity treatment</span> in a United States, according to a Reuters check that found Danish bank analysts had a top expectations.</p>
<p> Novo Nordisk, a world’s biggest insulin producer, is in proviso 3 of studies to use Victoza to provide <span>obesity</span> and expects a diagnosis to be launched in a United States late in of 2014 or early 2015.</p>
<p> Liraglutide, an active part in Victoza, has shown it can be effective in assisting portly people losing weight.</p>
<p> A consult of 10 <span>analysts</span> found an normal foresee of a 43 percent possibility of Victoza being authorized by a <span>U.S. Food and Drug Administration</span> as an plumpness treatment, with analysts from <spa...